1,176 results match your criteria: "Nagano Red Cross Hospital; T. Fujibayashi[Affiliation]"
J Med Ultrason (2001)
January 2023
Medical Check-Up Center, JA Hokkaido P.W.F.A.C. Obihiro Kosei General Hospital, Hokkaido, Japan.
Oncology
June 2023
Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy,
Eur Heart J Cardiovasc Imaging
March 2023
Biomedical Imaging Laboratory, Graduate School of Biomedical Engineering, Tohoku University, 6-6-05 Aramaki Aza Aoba, Aobaku, Sendai 980-8579, Japan.
Thorac Cancer
February 2023
First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Background: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C-reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil-to-lymphocyte ratio (C-PLAN) are useful biomarkers for predicting the prognosis of NSCLC; however, there are no reports examining the C-PLAN index, which combines these five factors in a single prognostic factor.
View Article and Find Full Text PDFInt J Hematol
February 2023
Department of Pediatrics, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Cancer Sci
April 2023
Department of Hematology, Nippon Medical School, Tokyo, Japan.
Nucleophosmin1 (NPM1) mutations are the most frequently detected gene mutations in acute myeloid leukemia (AML) and are considered a favorable prognostic factor. We retrospectively analyzed the prognosis of 605 Japanese patients with de novo AML, including 174 patients with NPM1-mutated AML. Although patients with NPM1-mutated AML showed a high remission rate, this was not a favorable prognostic factor for overall survival (OS); this is contrary to generally accepted guidelines.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
February 2023
Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Background: Bone marrow (BM) fibrosis is a condition characterized by deposition of reticulin and collagen fibers in BM. It may confer a poor prognosis in some of hematological malignancies. However, the relationship between fibrosis and the disease pathology is not fully understood and no biomarkers for BM fibrosis are available in clinical practice.
View Article and Find Full Text PDFRadiat Prot Dosimetry
March 2023
Department of Radiology, Fujiyoshida Municipal Hospital, Yamanashi, Japan.
This study presents a new idea for estimating the number of measurements required for determining the uncertainty in obtaining the desired water absorbed dose using the variation obtained from multicenter absorbed dose measurement data. The number of dose measurements depends on the performance of each linear accelerator (LINAC) tested and the dosimetry equipment and procedure used. However, optimising the number of data collected for the absorbed dose to water has been inadequately reported.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2023
Azumino Red Cross Hospital, Nagano, Japan.
Introduction: Accessory spleen torsion is extremely rare, and surgery is often the emergency or elective treatment of choice.
Presentation Of Case: A 20-year-old female with no specific medical history presented to our outpatient clinic with a chief complaint of abdominal pain. The patient was diagnosed with accessory spleen torsion by computed tomography.
Cureus
November 2022
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, JPN.
Angioedema is a rare but potentially lethal side effect of angiotensin-converting enzyme inhibitors (ACEIs). Most ACEI-induced angioedema (ACEI-AE) cases have been reported in adults, with few reports of cases in children. Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder that presents with acute onset of symptoms, including headache, vomiting, visual disturbances, and seizures.
View Article and Find Full Text PDFEur J Cancer
February 2023
Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - Univeristy of Bologna, Bologna, Italy.
Cancer Med
April 2023
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Aim: To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev).
Methods: A total of 286 patients with unresectable HCC treated with Atez/Bev as first-line systematic therapy were included.
Results: Regarding treatment-related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%.
Introduction: Haemophilia B patients with factor IX inhibitors have particularly unmet needs for conventional therapy.
Aim: Phase II/III clinical trial, multicentre, open-label, prospective, self-controlled study was conducted to assess MC710 prophylaxis in haemophilia B patients with inhibitors.
Methods: We enrolled haemophilia patients who had received episodic or prophylactic treatment with bypassing agents up to that time.
J Cancer Res Clin Oncol
August 2023
Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.
Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea).
Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab.
Pediatr Blood Cancer
February 2023
Japan Children's Cancer Group (JCCG), Tokyo, Japan.
We conducted a cross-sectional study using a questionnaire to explore the late effects in survivors of allogenic hematopoietic stem cell transplantation (HSCT) for juvenile myelomonocytic leukemia (JMML). The attending pediatric hematologists/oncologists completed the questionnaires. Of the 30 survivors, approximately 83% showed more than one late effect.
View Article and Find Full Text PDFCancer Med
March 2023
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Allergol Int
April 2023
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Oncology
April 2023
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Introduction: This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/bev).
Methods: The study analyzed 485 HCC patients treated with Atez/bev.
Results: There were 342 patients with a low PNI (<47) and 143 patients with a high PNI (≥47).
Background: Bulimia nervosa (BN) and the binge-eating/purging subtype of anorexia nervosa (b/p AN) are characterized by binge eating and unsafe compensatory behaviors, such as laxatives or diuretic abuse, self-induced vomiting, and excessive exercise. BN often causes miscellaneous physical complications that can lead to death. However, there have been very few prior reports on the physical complications of chronic BN.
View Article and Find Full Text PDFJ Crit Care
February 2023
Department of Respiratory Medicine, Ichinomiyanishi Hospital, 1 Kaimeihira, Ichinomiya, Aichi 494-0001, Japan.
Hepatol Res
March 2023
Department of Gastroenterology, Nara Medical University, Nara, Japan.
J Obstet Gynaecol Res
February 2023
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hepatol Int
February 2023
Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Hypertens Res
February 2023
Department of Cardiovascular Medicine, Saga University, Saga, Japan.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce the risk of heart failure progression and mortality rates. Moreover, osmotic diuresis induced by SGLT2 inhibition may result in an improved heart failure prognosis. Independent of conventional diuretics in patients with type 2 diabetes (T2D) and chronic heart failure, especially in patients with heart failure with preserved ejection fraction (HFpEF), it is unclear whether SGLT2i chronically reduces estimated plasma volume (ePV).
View Article and Find Full Text PDFBone Marrow Transplant
February 2023
Department of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Ishikawa, 920-8641, Japan.